FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379095557> ?p ?o ?g. }

• W4379095557 endingPage "e33925" @default.
• W4379095557 startingPage "e33925" @default.
• W4379095557 abstract "Background: We conducted a meta-analysis to systematically evaluate the efficacy and safety of treatment with or without pertuzumab for human epidermal growth factor receptor-2 -positive (HER2)-positive breast cancer and provided evidence-based reference for clinical use. Methods: The Cochrane Library, PubMed, EMbase, Clinical Trials and Web of Science databases were searched for studies published up to July 2022, which reported clinical randomized controlled trials of treatment in combination with pertuzumab (experimental group) and without pertuzumab (control group) for HER2-positive breast cancer. Meta-analysis was performed using R 4.2.1 based on the extraction of the data and the risk of bias assessment under the supervision of the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. Results: The results from this study showed that, the patients in the experimental group showed prolonged progression-free survival [hazard ratio = 0.72, 95% confidence interval (CI) (0.65,0.80), P < .01] and overall survival [hazard ratio = 0.80, 95% CI (0.66,0.96), P = .02] than those in the control group. In terms of safety, the incidence of grade ≥ 3 adverse events including diarrhea [risk ratio (RR) = 2.36, 95% CI (1.98,2.81), P < .01] and anemia [RR = 1.43, 95% CI (1.17,1.75), P < .01] in the experimental group were significantly higher than those in the control group. The incidence of common adverse events, that is rash in the experimental group was significantly higher than that in the control group [RR = 1.62, 95% CI (1.38,1.90), P < .01]. Conclusion: These results support that the treatment in combination with pertuzumab is superior to the treatment in combination without pertuzumab in the treatment of HER2-positive breast cancer, but there are some adverse effects such as diarrhea, anemia, and rash, which should be carefully monitored in clinical practice." @default.
• W4379095557 created "2023-06-03" @default.
• W4379095557 creator A5000292631 @default.
• W4379095557 creator A5035477485 @default.
• W4379095557 creator A5073483518 @default.
• W4379095557 creator A5079477209 @default.
• W4379095557 date "2023-06-02" @default.
• W4379095557 modified "2023-09-23" @default.
• W4379095557 title "Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis" @default.
• W4379095557 cites W2001195460 @default.
• W4379095557 cites W2002387745 @default.
• W4379095557 cites W2098923148 @default.
• W4379095557 cites W2138977450 @default.
• W4379095557 cites W2143352606 @default.
• W4379095557 cites W2148050448 @default.
• W4379095557 cites W2156098321 @default.
• W4379095557 cites W2266665237 @default.
• W4379095557 cites W2269332562 @default.
• W4379095557 cites W2379981061 @default.
• W4379095557 cites W2401544943 @default.
• W4379095557 cites W2409096632 @default.
• W4379095557 cites W246286872 @default.
• W4379095557 cites W2546933023 @default.
• W4379095557 cites W2551315898 @default.
• W4379095557 cites W2560406314 @default.
• W4379095557 cites W2588681363 @default.
• W4379095557 cites W2609953159 @default.
• W4379095557 cites W2615421777 @default.
• W4379095557 cites W2624590002 @default.
• W4379095557 cites W2810369514 @default.
• W4379095557 cites W2886904628 @default.
• W4379095557 cites W2890864210 @default.
• W4379095557 cites W2904779531 @default.
• W4379095557 cites W2913467766 @default.
• W4379095557 cites W2957213237 @default.
• W4379095557 cites W2981669117 @default.
• W4379095557 cites W2982154937 @default.
• W4379095557 cites W3010282689 @default.
• W4379095557 cites W3012380787 @default.
• W4379095557 cites W3022903699 @default.
• W4379095557 cites W3036403354 @default.
• W4379095557 cites W3117303512 @default.
• W4379095557 cites W3165174637 @default.
• W4379095557 cites W3171709380 @default.
• W4379095557 cites W3172717265 @default.
• W4379095557 cites W3179982079 @default.
• W4379095557 cites W4211032970 @default.
• W4379095557 cites W4214901572 @default.
• W4379095557 cites W4241886935 @default.
• W4379095557 cites W4283588637 @default.
• W4379095557 cites W4294215472 @default.
• W4379095557 doi "https://doi.org/10.1097/md.0000000000033925" @default.
• W4379095557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37266600" @default.
• W4379095557 hasPublicationYear "2023" @default.
• W4379095557 type Work @default.
• W4379095557 citedByCount "0" @default.
• W4379095557 crossrefType "journal-article" @default.
• W4379095557 hasAuthorship W4379095557A5000292631 @default.
• W4379095557 hasAuthorship W4379095557A5035477485 @default.
• W4379095557 hasAuthorship W4379095557A5073483518 @default.
• W4379095557 hasAuthorship W4379095557A5079477209 @default.
• W4379095557 hasBestOaLocation W43790955571 @default.
• W4379095557 hasConcept C120665830 @default.
• W4379095557 hasConcept C121332964 @default.
• W4379095557 hasConcept C121608353 @default.
• W4379095557 hasConcept C126322002 @default.
• W4379095557 hasConcept C143998085 @default.
• W4379095557 hasConcept C168563851 @default.
• W4379095557 hasConcept C197934379 @default.
• W4379095557 hasConcept C207103383 @default.
• W4379095557 hasConcept C2776478404 @default.
• W4379095557 hasConcept C2779786085 @default.
• W4379095557 hasConcept C2780439572 @default.
• W4379095557 hasConcept C2781164504 @default.
• W4379095557 hasConcept C44249647 @default.
• W4379095557 hasConcept C530470458 @default.
• W4379095557 hasConcept C61511704 @default.
• W4379095557 hasConcept C71924100 @default.
• W4379095557 hasConcept C82789193 @default.
• W4379095557 hasConcept C95190672 @default.
• W4379095557 hasConceptScore W4379095557C120665830 @default.
• W4379095557 hasConceptScore W4379095557C121332964 @default.
• W4379095557 hasConceptScore W4379095557C121608353 @default.
• W4379095557 hasConceptScore W4379095557C126322002 @default.
• W4379095557 hasConceptScore W4379095557C143998085 @default.
• W4379095557 hasConceptScore W4379095557C168563851 @default.
• W4379095557 hasConceptScore W4379095557C197934379 @default.
• W4379095557 hasConceptScore W4379095557C207103383 @default.
• W4379095557 hasConceptScore W4379095557C2776478404 @default.
• W4379095557 hasConceptScore W4379095557C2779786085 @default.
• W4379095557 hasConceptScore W4379095557C2780439572 @default.
• W4379095557 hasConceptScore W4379095557C2781164504 @default.
• W4379095557 hasConceptScore W4379095557C44249647 @default.
• W4379095557 hasConceptScore W4379095557C530470458 @default.
• W4379095557 hasConceptScore W4379095557C61511704 @default.
• W4379095557 hasConceptScore W4379095557C71924100 @default.
• W4379095557 hasConceptScore W4379095557C82789193 @default.
• W4379095557 hasConceptScore W4379095557C95190672 @default.

• next